PlexusDx offers compounded GLP-1 medications from licensed 503A pharmacies at lower cost, with optional genetic pathway testing and greater medication flexibility
The GLP-1 obesity market, already valued at $8.21 billion in 2025 and projected to reach $66.57 billion by 2035, is the commercial backdrop, but this is still phase 3 data without regulatory submission announced
Retatrutide has not been formally identified as a cause of hair loss in published clinical trial data, unlike semaglutide and tirzepatide where post-marketing hair shedding reports have been submitted
That is the right design principle
Understanding your 150+ genetic insights helps your provider personalize your meal schedule and food choices for your unique peptide pathways, available for $99 after your first month of treatment
BPC-157 is a gastric-derived peptide studied for cytoprotection and tissue protection, while TB-500 is a thymosin beta-4 fragment studied for cell migration and angiogenesis
